相关实验视频

Updated: Jul 15, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

肝细胞癌的质子束疗法:日本的多中心前性注册表研究

Masashi Mizumoto¹, Hiroyuki Ogino², Toshiyuki Okumura¹

¹Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, 305-8576, Japan.

International journal of radiation oncology, biology, physics

|October 1, 2023

概括

质子束疗法 (PBT) 对肝细胞癌 (HCC) 显示出良好的疗效,其3年局部控制率为90%. 这种治疗也表明,HCC患者晚期严重不良事件的风险较低.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

肝细胞癌 (HCC) 是一种主要的肝癌,具有显著的全球健康影响.
质子束疗法 (PBT) 是一种先进的放射治疗形式,提供精确的剂量传递.
评估PBT在HCC中的有效性和安全性对于治疗优化至关重要.

研究的目的:

评估质子束疗法 (PBT) 治疗肝细胞癌 (HCC) 的有效性和安全性.
在日本建立一个潜在的多中心注册表,以收集关于HCC的PBT的数据.

主要方法:

从2016年5月到2018年6月,在日本进行了一项前性的多中心注册表研究.
分析了从576名接受初始PBT的HCC患者的数据.
关键终点包括整体存活率 (OS),无进展存活率 (PFS) 和局部复发率.

主要成果:

平均寿命为48.8个月,4年生存率为50.1%.
中位数的PFS为14.7个月,4年PFS率为22.8%.
较高的OS率与较小的瘤大小,更好的Child-Pugh得分以及与胃肠道的距离更大有关. 3级或更高的晚期不良事件发生在4.7%的患者中.

结论:

质子束疗法 (PBT) 对肝细胞癌 (HCC) 显示出良好的治疗效果.
该研究表明,在HCC中,PBT的3年局部控制率约为90%.
对HCC的PBT与晚期严重不良事件的低风险有关.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...